Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: Long-term results in a small case series

J. B. Reed, J. W. Briggs, J. C. McDonald, W. R. Freeman, Lawrence S Morse

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To report the stability of acquired immunodeficiency syndrome (AIDS)-associated cytomegalovirus (CMV) retinitis lesions that have undergone regression in the absence of specific anti-CMV medications owing to highly active antiretroviral therapy (HAART)-generated immune recovery. Methods: The initial examination revealed HAART-associated regression of CMV retinitis lesions in eight subjects at two institutions. Patients were monitored for recurrences of CMV activity. CD4+ T-lymphocyte counts and human immunodeficiency virus (HIV) loads were measured. Results: All patients had positive initial responses to HAART with an average HIV load decrease of 2.26 log units (range 0.3-5.57). Mean CD4+ T-lymphocyte count at baseline was 45.6 (range 4-107) and increased by an average of 132.5 (range 7-266) within the first 2 to 4 months of HAART. Patients were observed for an average of 15.5 months (range 11-20 months). Six subjects had a vigorous and sustained response to therapy, achieving an average HIV load of 9,400 copies/mL (3.32 log10 decrease) and CD4+ T-lymphocyte count of 158.2 cells/μL. These patients had no CMV retinitis progression. By contrast, two others who attained an average log10 decrease of only 0.48 had modest and short-lived increases in the CD4+ T-lymphocyte count. These patients experienced reactivation of CMV retinitis after 5 and 7 months, respectively. Conclusions: Regressed CMV retinitis may remain healed for long periods. However, failure of HAART to induce substantial decreases in HIV load may predict poor or unsustainable rises in the CD4+ T-lymphocyte count and presage recurrence of CMV retinitis. Vigilance in ophthalmic examinations is especially mandatory in these subjects.

Original languageEnglish (US)
Pages (from-to)339-343
Number of pages5
JournalRetina
Volume21
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Cytomegalovirus Retinitis
Highly Active Antiretroviral Therapy
CD4 Lymphocyte Count
T-Lymphocytes
HIV
Cytomegalovirus
Recurrence
Acquired Immunodeficiency Syndrome

Keywords

  • Acquired immunodeficiency virus
  • Cytomegalovirus retinitis
  • Highly active antiretroviral therapy
  • Immune recovery

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis : Long-term results in a small case series. / Reed, J. B.; Briggs, J. W.; McDonald, J. C.; Freeman, W. R.; Morse, Lawrence S.

In: Retina, Vol. 21, No. 4, 2001, p. 339-343.

Research output: Contribution to journalArticle

Reed, J. B. ; Briggs, J. W. ; McDonald, J. C. ; Freeman, W. R. ; Morse, Lawrence S. / Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis : Long-term results in a small case series. In: Retina. 2001 ; Vol. 21, No. 4. pp. 339-343.
@article{69880f6e0c75498d89ae5d26b70c3a84,
title = "Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: Long-term results in a small case series",
abstract = "Purpose: To report the stability of acquired immunodeficiency syndrome (AIDS)-associated cytomegalovirus (CMV) retinitis lesions that have undergone regression in the absence of specific anti-CMV medications owing to highly active antiretroviral therapy (HAART)-generated immune recovery. Methods: The initial examination revealed HAART-associated regression of CMV retinitis lesions in eight subjects at two institutions. Patients were monitored for recurrences of CMV activity. CD4+ T-lymphocyte counts and human immunodeficiency virus (HIV) loads were measured. Results: All patients had positive initial responses to HAART with an average HIV load decrease of 2.26 log units (range 0.3-5.57). Mean CD4+ T-lymphocyte count at baseline was 45.6 (range 4-107) and increased by an average of 132.5 (range 7-266) within the first 2 to 4 months of HAART. Patients were observed for an average of 15.5 months (range 11-20 months). Six subjects had a vigorous and sustained response to therapy, achieving an average HIV load of 9,400 copies/mL (3.32 log10 decrease) and CD4+ T-lymphocyte count of 158.2 cells/μL. These patients had no CMV retinitis progression. By contrast, two others who attained an average log10 decrease of only 0.48 had modest and short-lived increases in the CD4+ T-lymphocyte count. These patients experienced reactivation of CMV retinitis after 5 and 7 months, respectively. Conclusions: Regressed CMV retinitis may remain healed for long periods. However, failure of HAART to induce substantial decreases in HIV load may predict poor or unsustainable rises in the CD4+ T-lymphocyte count and presage recurrence of CMV retinitis. Vigilance in ophthalmic examinations is especially mandatory in these subjects.",
keywords = "Acquired immunodeficiency virus, Cytomegalovirus retinitis, Highly active antiretroviral therapy, Immune recovery",
author = "Reed, {J. B.} and Briggs, {J. W.} and McDonald, {J. C.} and Freeman, {W. R.} and Morse, {Lawrence S}",
year = "2001",
language = "English (US)",
volume = "21",
pages = "339--343",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis

T2 - Long-term results in a small case series

AU - Reed, J. B.

AU - Briggs, J. W.

AU - McDonald, J. C.

AU - Freeman, W. R.

AU - Morse, Lawrence S

PY - 2001

Y1 - 2001

N2 - Purpose: To report the stability of acquired immunodeficiency syndrome (AIDS)-associated cytomegalovirus (CMV) retinitis lesions that have undergone regression in the absence of specific anti-CMV medications owing to highly active antiretroviral therapy (HAART)-generated immune recovery. Methods: The initial examination revealed HAART-associated regression of CMV retinitis lesions in eight subjects at two institutions. Patients were monitored for recurrences of CMV activity. CD4+ T-lymphocyte counts and human immunodeficiency virus (HIV) loads were measured. Results: All patients had positive initial responses to HAART with an average HIV load decrease of 2.26 log units (range 0.3-5.57). Mean CD4+ T-lymphocyte count at baseline was 45.6 (range 4-107) and increased by an average of 132.5 (range 7-266) within the first 2 to 4 months of HAART. Patients were observed for an average of 15.5 months (range 11-20 months). Six subjects had a vigorous and sustained response to therapy, achieving an average HIV load of 9,400 copies/mL (3.32 log10 decrease) and CD4+ T-lymphocyte count of 158.2 cells/μL. These patients had no CMV retinitis progression. By contrast, two others who attained an average log10 decrease of only 0.48 had modest and short-lived increases in the CD4+ T-lymphocyte count. These patients experienced reactivation of CMV retinitis after 5 and 7 months, respectively. Conclusions: Regressed CMV retinitis may remain healed for long periods. However, failure of HAART to induce substantial decreases in HIV load may predict poor or unsustainable rises in the CD4+ T-lymphocyte count and presage recurrence of CMV retinitis. Vigilance in ophthalmic examinations is especially mandatory in these subjects.

AB - Purpose: To report the stability of acquired immunodeficiency syndrome (AIDS)-associated cytomegalovirus (CMV) retinitis lesions that have undergone regression in the absence of specific anti-CMV medications owing to highly active antiretroviral therapy (HAART)-generated immune recovery. Methods: The initial examination revealed HAART-associated regression of CMV retinitis lesions in eight subjects at two institutions. Patients were monitored for recurrences of CMV activity. CD4+ T-lymphocyte counts and human immunodeficiency virus (HIV) loads were measured. Results: All patients had positive initial responses to HAART with an average HIV load decrease of 2.26 log units (range 0.3-5.57). Mean CD4+ T-lymphocyte count at baseline was 45.6 (range 4-107) and increased by an average of 132.5 (range 7-266) within the first 2 to 4 months of HAART. Patients were observed for an average of 15.5 months (range 11-20 months). Six subjects had a vigorous and sustained response to therapy, achieving an average HIV load of 9,400 copies/mL (3.32 log10 decrease) and CD4+ T-lymphocyte count of 158.2 cells/μL. These patients had no CMV retinitis progression. By contrast, two others who attained an average log10 decrease of only 0.48 had modest and short-lived increases in the CD4+ T-lymphocyte count. These patients experienced reactivation of CMV retinitis after 5 and 7 months, respectively. Conclusions: Regressed CMV retinitis may remain healed for long periods. However, failure of HAART to induce substantial decreases in HIV load may predict poor or unsustainable rises in the CD4+ T-lymphocyte count and presage recurrence of CMV retinitis. Vigilance in ophthalmic examinations is especially mandatory in these subjects.

KW - Acquired immunodeficiency virus

KW - Cytomegalovirus retinitis

KW - Highly active antiretroviral therapy

KW - Immune recovery

UR - http://www.scopus.com/inward/record.url?scp=0034890188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034890188&partnerID=8YFLogxK

M3 - Article

C2 - 11508879

AN - SCOPUS:0034890188

VL - 21

SP - 339

EP - 343

JO - Retina

JF - Retina

SN - 0275-004X

IS - 4

ER -